skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Gail

+24 year(s) experience

Gail Parziale Pharma Intelligence
Gail Parziale manages, develops and strategically plans editorial operations for our content teams. She has broad responsibility for our key products including Biomedtracker, Chinatrove, Meddevicetracker, Medtrack, Trialtrove and Pharmaprojects.

Gail enjoys working on projects that help bring life-saving medicines to market faster. Before her current role in operations and knowledge process outsourcing, she worked as a Senior Analyst and Director in the Cardiovascular and Metabolic team. She later moved on to become responsible for the team’s editorial process.

 

Before joining Citeline in 2004, Gail managed a portfolio of business intelligence reports that focused on various therapy markets and emerging technologies. She was responsible for selecting report topics, conducting extensive market research, analyzing clinical trial data, and writing final report content.

Specialties

  • Commercial Strategy
  • Clinical Trials

Gail Writes For

Analyst Articles

Articles by Kevin

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    Pharma Can Reset Reputation In Pandemic Says Novartis CEO

    Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

    Topic Coronavirus

    article

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    Another Alzheimer's Setback As Roche And Lilly Drugs Fail

    As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

    Topic Alzheimer's Disease

    View article

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    The Healthcare World According To Andrew Witty

    The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies can lead to simpler, more cost-effective health systems.

    Topic digital-health

    article

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    J&J's Spravato Set For EU Launches Soon

    Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

    Topic drug-approval drug-development-landscape

    article

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    Webinar: Q1 2019 Sales and Earnings

    Scrip editors will dissect Q1 sales and earnings reports of top pharma companies and focus on key trends, developments, and projected future impact.

    Full video

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

    Topic cell-and-gene-therapy

    article